Meet Ivan
63-year-old carpenter who is anticipating his daughter’s graduation from college as she is the first in the family.
I got sick pretty fast from my kidney cancer. They say it’s not good, but my daughter is graduating from college in a few months—seeing her get her degree—it’s all I want.”
MEDICAL HISTORY: Has anemia and presented with blood in his urine
INITIAL DIAGNOSIS: Advanced renal cell carcinoma (RCC) with a clear cell histology and neoplastic metastatic disease; scheduled for radiotherapy
CURRENT STATUS:
- RCC is metastatic and Ivan is treatment naïve
- ECOG performance status: 1
- MSKCC risk: intermediate
- Karnofsky performance status (KPS): 70%
In COMPARZ, VOTRIENT demonstrated efficacy across a wide range of patients1,2:
85% of patients had a favorable or intermediate MSKCC risk
75% of patients had a 90 or 100 KPS
Patient age ranged from 18 to 88 years
When choosing first-line treatment, what therapy do you consider?
Hypothetical patient case study.
References: 1. VOTRIENT [summary of product characteristics]. Camberley, UK: Novartis Europharm Limited; February 2018. 2. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-731.
